All Search Results
-
A novel wearable system for monitoring and alerting for seizures and cardiorespiratory dysfunctions
A novel wearable system for monitoring and alerting for seizures and cardiorespiratory dysfunctions
-
Total Therapy for Infants With Acute Lymphoblastic Leukemia II
TINI 2: Total Therapy for Infants with Acute Lymphoblastic Leukemia II
-
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
-
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
-
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
-
Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
-
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
A Phase 2 Study of Revumenib (SNDX-5613) in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia
-
CAR: Complex Aneurysm Registry - Real-World Evidence Data Collection for Intracranial Aneurysm Treatment Devices
CAR: Complex Aneurysm Registry - Real-World Evidence Data Collection for Intracranial Aneurysm Treatment Devices
-
A Multi-Center Post-Market Retrospective Data Collection Protocol to Evaluate the Real World Performance of Orthofix Spine Stim Devices Compared to Control
A Multi-Center Post-Market Retrospective Data Collection Protocol to Evaluate the Real World Performance of Orthofix Spine Stim Devices Compared to Control
-
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
